Delaware | 26-2940963 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
10005 Muirlands Blvd. Suite G, Irvine, California | 92618 | |
(Address of Principal Executive Offices) | (Zip Code) |
Large accelerated filer [ ] | Accelerated filer [ ] |
Non-accelerated filer [ ] | Smaller reporting company [X] |
(Do not check if smaller reporting company) |
ChromaDex Corporation and Subsidiaries
|
||
Condensed Consolidated Balance Sheets (Unaudited)
|
||
September 27, 2014 and December 28, 2013
|
September 27, 2014
|
December 28, 2013
|
|||||||
Assets
|
||||||||
Current Assets
|
||||||||
Cash
|
$ | 1,203,758 | $ | 2,261,336 | ||||
Trade receivables, less allowance for doubtful accounts and returns
September 27, 2014 $33,000; December 28, 2013 $9,000
|
2,528,638 | 838,793 | ||||||
Other receivable
|
- | 215,000 | ||||||
Inventories
|
2,286,086 | 2,204,125 | ||||||
Prepaid expenses and other assets
|
294,296 | 271,445 | ||||||
Total current assets
|
6,312,778 | 5,790,699 | ||||||
Leasehold Improvements and Equipment, net
|
1,293,702 | 1,063,239 | ||||||
Other Noncurrent Assets
|
||||||||
Deposits
|
52,046 | 43,460 | ||||||
Long-term investment in affiliate
|
773,801 | 1,887,844 | ||||||
Intangible assets, net
|
266,824 | 201,650 | ||||||
Total other noncurrent assets
|
1,092,671 | 2,132,954 | ||||||
Total assets
|
$ | 8,699,151 | $ | 8,986,892 | ||||
Liabilities and Stockholders' Equity
|
||||||||
Current Liabilities
|
||||||||
Accounts payable
|
$ | 2,270,645 | $ | 1,440,910 | ||||
Accrued expenses
|
857,854 | 656,707 | ||||||
Current maturities of capital lease obligations
|
162,566 | 138,887 | ||||||
Customer deposits and other
|
225,917 | 546,044 | ||||||
Deferred rent, current
|
65,040 | 55,586 | ||||||
Total current liabilities
|
3,582,022 | 2,838,134 | ||||||
Capital lease obligations, less current maturities
|
456,969 | 280,342 | ||||||
Deferred rent, less current
|
156,779 | 202,965 | ||||||
Total liabilities
|
4,195,770 | 3,321,441 | ||||||
Commitments and contingencies
|
||||||||
Stockholders' Equity
|
||||||||
Common stock, $.001 par value; authorized 150,000,000 shares;
issued and outstanding September 27, 2014 105,239,985 and
December 28, 2013 104,524,738 shares
|
105,240 | 104,525 | ||||||
Additional paid-in capital
|
42,695,089 | 39,697,063 | ||||||
Accumulated deficit
|
(38,296,948 | ) | (34,136,137 | ) | ||||
Total stockholders' equity
|
4,503,381 | 5,665,451 | ||||||
Total liabilities and stockholders' equity
|
$ | 8,699,151 | $ | 8,986,892 | ||||
ChromaDex
Corporation and Subsidiaries
|
||
Condensed Consolidated Statements of Operations (Unaudited)
|
||
For the Three Month Periods Ended September 27, 2014 and September 28, 2013
|
September 27, 2014
|
September 28, 2013
|
|||||||
Sales, net
|
$ | 4,139,710 | $ | 2,718,207 | ||||
Cost of sales
|
2,616,764 | 1,968,020 | ||||||
Gross profit
|
1,522,946 | 750,187 | ||||||
Operating expenses:
|
||||||||
Sales and marketing
|
518,662 | 505,068 | ||||||
General and administrative
|
1,651,718 | 1,453,611 | ||||||
Loss from investment in affiliate
|
- | 33,281 | ||||||
Operating expenses
|
2,170,380 | 1,991,960 | ||||||
Operating loss
|
(647,434 | ) | (1,241,773 | ) | ||||
Nonoperating income (expense):
|
||||||||
Interest income
|
230 | 179 | ||||||
Interest expense
|
(12,449 | ) | (8,669 | ) | ||||
Nonoperating expenses
|
(12,219 | ) | (8,490 | ) | ||||
Net loss
|
$ | (659,653 | ) | $ | (1,250,263 | ) | ||
Basic and Diluted loss per common share
|
$ | (0.01 | ) | $ | (0.01 | ) | ||
Basic and Diluted weighted average common shares outstanding
|
106,610,400 | 101,309,939 | ||||||
ChromaDex
Corporation and Subsidiaries
|
||
Condensed Consolidated Statements of Operations (Unaudited)
|
||
For the Nine Month Periods Ended September 27, 2014 and September 28, 2013
|
September 27, 2014
|
September 28, 2013
|
|||||||
Sales, net
|
$ | 11,070,002 | $ | 7,759,668 | ||||
Cost of sales
|
7,163,282 | 5,375,903 | ||||||
Gross profit
|
3,906,720 | 2,383,765 | ||||||
Operating expenses:
|
||||||||
Sales and marketing
|
1,554,777 | 1,866,051 | ||||||
General and administrative
|
6,458,027 | 4,155,792 | ||||||
Loss from investment in affiliate
|
21,543 | 33,281 | ||||||
Operating expenses
|
8,034,347 | 6,055,124 | ||||||
Operating loss
|
(4,127,627 | ) | (3,671,359 | ) | ||||
Nonoperating income (expense):
|
||||||||
Interest income
|
1,175 | 679 | ||||||
Interest expense
|
(34,359 | ) | (24,521 | ) | ||||
Nonoperating expenses
|
(33,184 | ) | (23,842 | ) | ||||
Net loss
|
$ | (4,160,811 | ) | $ | (3,695,201 | ) | ||
Basic and Diluted loss per common share
|
$ | (0.04 | ) | $ | (0.04 | ) | ||
Basic and Diluted weighted average common shares outstanding
|
106,290,782 | 98,590,008 | ||||||
ChromaDex
Corporation and Subsidiaries
|
|||||
Condensed Consolidated Statement of Stockholders' Equity (Unaudited)
|
|||||
For the Nine Month Period Ended September 27, 2014
|
Common Stock
|
Additional
Paid-in
|
Accumulated
|
Total
Stockholders'
|
|||||||||||||||||
Shares
|
Amount
|
Capital
|
Deficit
|
Equity
|
||||||||||||||||
Balance, December 28, 2013
|
104,524,738 | $ | 104,525 | $ | 39,697,063 | $ | (34,136,137 | ) | $ | 5,665,451 | ||||||||||
Exercise of stock options
|
34,363 | 34 | 27,066 | - | 27,100 | |||||||||||||||
Issuance of unvested restricted stock
|
1,090,000 | 1,090 | - | - | 1,090 | |||||||||||||||
Unvested restricted stock
|
(1,090,000 | ) | (1,090 | ) | - | - | (1,090 | ) | ||||||||||||
Share-based compensation
|
- | - | 949,943 | - | 949,943 | |||||||||||||||
Net loss
|
- | - | - | (1,848,016 | ) | (1,848,016 | ) | |||||||||||||
Balance, March 29, 2014
|
104,559,101 | $ | 104,559 | $ | 40,674,072 | $ | (35,984,153 | ) | $ | 4,794,478 | ||||||||||
Exercise of stock options
|
24,136 | 24 | 17,971 | - | 17,995 | |||||||||||||||
Issuance of unvested restricted stock
|
96,000 | 96 | - | - | 96 | |||||||||||||||
Unvested restricted stock
|
(96,000 | ) | (96 | ) | - | - | (96 | ) | ||||||||||||
Share-based compensation
|
6,000 | 6 | 1,030,689 | - | 1,030,695 | |||||||||||||||
Stock issued to settle outstanding payable balance
|
126,605 | 127 | 128,367 | - | 128,494 | |||||||||||||||
Net loss
|
- | - | - | (1,653,142 | ) | (1,653,142 | ) | |||||||||||||
Balance, June 28, 2014
|
104,715,842 | $ | 104,716 | $ | 41,851,099 | $ | (37,637,295 | ) | $ | 4,318,520 | ||||||||||
Exercise of stock options
|
453,143 | 453 | 403,610 | - | 404,063 | |||||||||||||||
Share-based compensation
|
71,000 | 71 | 431,380 | - | 431,451 | |||||||||||||||
Stock issued to settle outstanding payable balance
|
- | - | 9,000 | - | 9,000 | |||||||||||||||
Net loss
|
- | - | - | (659,653 | ) | (659,653 | ) | |||||||||||||
Balance, September 27, 2014
|
105,239,985 | $ | 105,240 | $ | 42,695,089 | $ | (38,296,948 | ) | $ | 4,503,381 | ||||||||||
ChromaDex
Corporation and Subsidiaries
|
||
Condensed Consolidated Statements of Cash Flows (Unaudited)
|
||
For the Nine Month Periods Ended September 27, 2014 and September 28, 2013
|
September 27, 2014
|
September 28, 2013
|
|||||||
Cash Flows From Operating Activities
|
||||||||
Net loss
|
$ | (4,160,811 | ) | $ | (3,695,201 | ) | ||
Adjustments to reconcile net loss to net cash
used in operating activities:
|
||||||||
Depreciation of leasehold improvements and equipment
|
161,712 | 187,667 | ||||||
Amortization of intangibles
|
24,826 | 16,819 | ||||||
Share-based compensation expense
|
2,467,720 | 1,059,653 | ||||||
Gain on exchange of equipment
|
(17,301 | ) | - | |||||
Loss from disposal of equipment
|
- | 68,378 | ||||||
Loss from investment in affiliate
|
21,543 | 33,281 | ||||||
Changes in operating assets and liabilities:
|
||||||||
Trade receivables
|
(1,689,845 | ) | 931,904 | |||||
Other receivable
|
215,000 | - | ||||||
Inventories
|
(81,961 | ) | (479,924 | ) | ||||
Prepaid expenses and other assets
|
(87,068 | ) | (50,991 | ) | ||||
Accounts payable
|
967,229 | (712,138 | ) | |||||
Accrued expenses
|
201,147 | 72,336 | ||||||
Customer deposits and other
|
(320,127 | ) | 349,378 | |||||
Deferred rent
|
(36,732 | ) | 45,661 | |||||
Net cash used in operating activities
|
(2,334,668 | ) | (2,173,177 | ) | ||||
Cash Flows From Investing Activities
|
||||||||
Purchases of leasehold improvements and equipment
|
(53,428 | ) | (117,523 | ) | ||||
Purchases of intangible assets
|
(90,000 | ) | (69,000 | ) | ||||
Proceeds from sale of assets
|
- | 1,000,000 | ||||||
Proceeds from sale of equipment
|
1,356 | - | ||||||
Proceeds from investment in affiliate
|
1,092,500 | 225,000 | ||||||
Net cash provided by investing activities
|
950,428 | 1,038,477 | ||||||
Cash Flows From Financing Activities
|
||||||||
Proceeds from exercise of stock options
|
449,158 | 138,369 | ||||||
Proceeds from exercise of warrants
|
- | 1,638,748 | ||||||
Principal payments on capital leases
|
(122,496 | ) | (74,993 | ) | ||||
Net cash provided by financing activities
|
326,662 | 1,702,124 | ||||||
Net (decrease) increase in cash
|
(1,057,578 | ) | 567,424 | |||||
Cash Beginning of Period
|
2,261,336 | 520,000 | ||||||
Cash Ending of Period
|
$ | 1,203,758 | $ | 1,087,424 | ||||
Supplemental Disclosures of Cash Flow Information
|
||||||||
Cash payments for interest
|
$ | 34,359 | $ | 24,521 | ||||
Supplemental Schedule of Noncash Investing Activity
|
||||||||
Capital lease obligation incurred for purchases of equipment
|
$ | 322,802 | $ | 171,851 | ||||
Retirement of fully depreciated equipment - cost
|
$ | 56,110 | $ | - | ||||
Retirement of fully depreciated equipment - accumulated depreciation
|
$ | (56,110 | ) | $ | - | |||
Supplemental Schedule of Noncash Operating Activity
|
||||||||
Stock issued to settle outsanding payable balance
|
$ | 137,494 | $ | - | ||||
Supplemental Schedule of Noncash Share-based Compensation
|
||||||||
Stock awards issued for services rendered in prior period
|
$ | - | $ | 14,560 | ||||
Changes in prepaid expenses associated with share-based compensation
|
$ | 55,631 | $ | 119,375 | ||||
Supplemental Schedule of Noncash Activities Related to
|
||||||||
Sale of BluScience Consumer Product Line
|
||||||||
Assets transferred
|
$ | - | $ | 3,526,677 | ||||
Liabilities transferred
|
$ | - | $ | 368,873 | ||||
Carrying value of long-term investment in affiliate,
net of $1,000,000 cash proceeds
|
$ | - | $ | 2,157,804 | ||||
See Notes to Condensed Consolidated Financial Statements.
|
September 27, 2014
|
December 28, 2013
|
|||||||
Reference standards
|
$ | 1,715,507 | $ | 1,769,160 | ||||
Bulk ingredients
|
866,509 | 694,965 | ||||||
2,582,016 | 2,464,125 | |||||||
Less valuation allowance
|
295,930 | 260,000 | ||||||
$ | 2,286,086 | $ | 2,204,125 |
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
September 27, 2014
|
September 28, 2013
|
September 27, 2014
|
September 28, 2013
|
|||||||||||||
Net loss
|
$ | (659,653 | ) | $ | (1,250,263 | ) | $ | (4,160,811 | ) | $ | (3,695,201 | ) | ||||
Basic and diluted loss per common share
|
$ | (0.01 | ) | $ | (0.01 | ) | $ | (0.04 | ) | $ | (0.04 | ) | ||||
Weighted average common shares outstanding
(1)
:
|
106,610,400 | 101,309,939 | 106,290,782 | 98,590,008 | ||||||||||||
Potentially dilutive securities
(2)
:
|
||||||||||||||||
Stock options
|
13,890,766 | 13,609,700 | 13,890,766 | 13,609,700 | ||||||||||||
Warrants
|
- | 535,000 | - | 535,000 |
(1) Includes 1,676,175 and 500,000 weighted average nonvested shares of restricted stock for the three months ended September 27, 2014
and September 28, 2013, respectively, and 1,606,380 and 500,000 weighted average nonvested shares of restricted stock
for the nine months ended September 27, 2014 and September 28, 2013, respectively, which are participating securities
that feature voting and dividend rights.
|
||||||
(2) Excluded from the computation of loss per share as their impact is antidilutive.
|
December 31,
2013
|
||||||||
Sales
|
$ | 60,575 | ||||||
Gross profit
|
33,619 | |||||||
Net loss
|
$ | (435,208 | ) | |||||
Changes in Carrying Value and Ownership Percentage for ChromaDex Corporation
|
||||||||
Carrying
Value
|
Ownership
Percentage
|
|||||||
At December 28, 2013
|
$ | 1,887,844 | 4.9 | % | ||||
Company's share of NeutriSci's loss
for the three-month period ended December 31, 2013;
previously not recognized due to a three-month lag
|
(21,543 | ) | - | |||||
Proceeds from assignment of the Senior Note
|
(1,092,500 | ) | - | |||||
At December 30, 2013
|
$ | 773,801 | 4.9 | % |
September 27, 2014
|
December 28, 2013
|
|||||||
Laboratory equipment
|
$ | 3,028,644 | $ | 2,782,364 | ||||
Leasehold improvements
|
495,240 | 491,125 | ||||||
Computer equipment
|
329,737 | 372,851 | ||||||
Furniture and fixtures
|
13,039 | 18,313 | ||||||
Office equipment
|
7,877 | 7,877 | ||||||
Construction in progress
|
159,277 | 40,126 | ||||||
4,033,814 | 3,712,656 | |||||||
Less accumulated depreciation
|
2,740,112 | 2,649,417 | ||||||
$ | 1,293,702 | $ | 1,063,239 |
Nine Months Ended September 27, 2014
|
||||
Expected volatility
|
73.55 | % | ||
Expected dividends
|
0.00 | % | ||
Expected term
|
5.7 years
|
|||
Risk-free rate
|
1.86 | % |
Weighted Average
|
||||||||||||||||
Remaining
|
Aggregate
|
|||||||||||||||
Number of
|
Exercise
|
Contractual
|
Intrinsic
|
|||||||||||||
Shares
|
Price
|
Term
|
Value
|
|||||||||||||
Outstanding at December 28, 2013
|
12,113,655 | $ | 1.06 | 7.43 | ||||||||||||
Options Granted
|
2,033,987 | 1.37 | 10.00 | |||||||||||||
Options Classification from Employee
to Non-Employee
|
(113,151 | ) | 0.76 | |||||||||||||
Options Exercised
|
(511,642 | ) | 0.88 | |||||||||||||
Options Expired
|
(253,900 | ) | 1.00 | |||||||||||||
Options Forfeited
|
(628,634 | ) | 1.11 | |||||||||||||
Outstanding at September 27, 2014
|
12,640,315 | $ | 1.12 | 7.22 | $ | 1,475,920 | ||||||||||
Exercisable at September 27, 2014
|
8,822,108 | $ | 1.13 | 6.53 | $ | 1,071,805 |
Weighted Average
|
||||||||
Award-Date
|
||||||||
Shares
|
Fair Value
|
|||||||
Unvested shares at December 28, 2013
|
500,000 | $ | 0.69 | |||||
Granted
|
1,090,000 | 1.41 | ||||||
Vested
|
- | - | ||||||
Forfeited
|
- | - | ||||||
Unvested shares at September 27, 2014
|
1,590,000 | $ | 1.18 | |||||
Expected to Vest as of September 27, 2014
|
1,590,000 | $ | 1.18 |
Weighted Average
|
||||||||||||||||
Remaining
|
Aggregate
|
|||||||||||||||
Number of
|
Exercise
|
Contractual
|
Intrinsic
|
|||||||||||||
Shares
|
Price
|
Term
|
Value
|
|||||||||||||
Outstanding at December 28, 2013
|
847,300 | $ | 1.44 | 5.74 | ||||||||||||
Options Granted
|
90,000 | 1.24 | 10.00 | |||||||||||||
Options Classification from Employee
to Non-Employee
|
113,151 | 0.76 | ||||||||||||||
Options Exercised
|
- | - | ||||||||||||||
Options Forfeited
|
- | - | ||||||||||||||
Outstanding at September 27, 2014
|
1,050,451 | $ | 1.35 | 5.73 | $ | 64,067 | ||||||||||
Exercisable at September 27, 2014
|
960,451 | $ | 1.36 | 5.34 | $ | 64,067 | ||||||||||
Weighted Average
|
||||||||
Shares
|
Fair Value
|
|||||||
Unvested shares at December 28, 2013
|
- | $ | - | |||||
Granted
|
96,000 | 1.30 | ||||||
Vested
|
(12,000 | ) | 1.28 | |||||
Forfeited
|
- | - | ||||||
Unvested shares expected to vest at September 27, 2014
|
84,000 | $ | 1.06 |
●
|
Core standards, and contract services segment includes supply of phytochemical reference standards, which are small quantities of plant-based compounds typically used to research an array of potential attributes, reference materials, and related contract services.
|
●
|
Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients to the manufacturers of consumer products in various industries including the nutritional supplement, food and beverage and animal health industries.
|
●
|
Scientific and regulatory consulting segment which consist of providing scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks.
|
Core Standards
|
Scientific and
|
|||||||||||||||||||
and Contract
|
|
Regulatory
|
||||||||||||||||||
Three months ended
September 27, 2014
|
Services
segment
|
Ingredients
segment
|
Consulting segment
|
Other
|
Total
|
|||||||||||||||
Net sales
|
$ | 1,814,622 | $ | 2,031,250 | $ | 293,838 | $ | - | $ | 4,139,710 | ||||||||||
Cost of sales
|
1,239,356 | 1,200,790 | 176,618 | - | 2,616,764 | |||||||||||||||
Gross profit
|
575,266 | 830,460 | 117,220 | - | 1,522,946 | |||||||||||||||
Operating expenses:
|
||||||||||||||||||||
Sales and marketing
|
259,951 | 243,068 | 15,643 | - | 518,662 | |||||||||||||||
General and administrative
|
- | - | - | 1,651,718 | 1,651,718 | |||||||||||||||
Operating expenses
|
259,951 | 243,068 | 15,643 | 1,651,718 | 2,170,380 | |||||||||||||||
Operating income (loss)
|
$ | 315,315 | $ | 587,392 | $ | 101,577 | $ | (1,651,718 | ) | $ | (647,434 | ) |
Core Standards
|
Scientific and
|
|||||||||||||||||||
and Contract
|
|
Regulatory
|
||||||||||||||||||
Three months ended September 28, 2013 |
Services
segment
|
Ingredients
segment
|
Consulting segment
|
Other
|
Total
|
|||||||||||||||
Net sales
|
$ | 1,574,970 | $ | 780,489 | $ | 362,749 | $ | - | $ | 2,718,207 | ||||||||||
Cost of sales
|
1,309,562 | 484,511 | 173,947 | - | 1,968,020 | |||||||||||||||
Gross profit
|
265,408 | 295,977 | 188,802 | - | 750,187 | |||||||||||||||
Operating expenses:
|
||||||||||||||||||||
Sales and marketing
|
328,043 | 165,025 | 12,000 | - | 505,068 | |||||||||||||||
General and administrative
|
- | - | - | 1,453,611 | 1,453,611 | |||||||||||||||
Loss from investment in affiliate
|
- | - | - | 33,281 | 33,281 | |||||||||||||||
Operating expenses
|
328,043 | 165,025 | 12,000 | 1,486,892 | 1,991,960 | |||||||||||||||
Operating income (loss)
|
$ | (62,635 | ) | $ | 130,952 | $ | 176,802 | $ | (1,486,892 | ) | $ | (1,241,773 | ) |
Core Standards
|
||||||||||||||||||||
and Contract
|
|
Regulatory
|
||||||||||||||||||
Nine months ended September 27, 2014 |
Services segment
|
Ingredients
segment
|
Consulting segment
|
Other
|
Total
|
|||||||||||||||
Net sales
|
$ | 5,407,455 | $ | 4,889,431 | $ | 773,116 | $ | - | $ | 11,070,002 | ||||||||||
Cost of sales
|
3,728,521 | 2,962,505 | 472,256 | - | 7,163,282 | |||||||||||||||
Gross profit
|
1,678,934 | 1,926,926 | 300,860 | - | 3,906,720 | |||||||||||||||
Operating expenses:
|
||||||||||||||||||||
Sales and marketing
|
694,523 | 793,414 | 66,840 | - | 1,554,777 | |||||||||||||||
General and administrative
|
- | - | - | 6,458,027 | 6,458,027 | |||||||||||||||
Loss from investment in affiliate
|
- | - | - | 21,543 | 21,543 | |||||||||||||||
Operating expenses
|
694,523 | 793,414 | 66,840 | 6,479,570 | 8,034,347 | |||||||||||||||
Operating income (loss)
|
$ | 984,411 | $ | 1,133,512 | $ | 234,020 | $ | (6,479,570 | ) | $ | (4,127,627 | ) |
Core Standards
|
Scientific and
|
|||||||||||||||||||
and Contract
|
|
Regulatory
|
||||||||||||||||||
Nine months ended
September 28, 2013
|
Services segment
|
Ingredients
segment
|
Consulting segment
|
Other
|
Total
|
|||||||||||||||
Net sales
|
$ | 4,978,727 | $ | 2,032,616 | $ | 808,610 | $ | (60,285 | ) | $ | 7,759,668 | |||||||||
Cost of sales
|
3,661,772 | 1,260,697 | 452,479 | 955 | 5,375,903 | |||||||||||||||
Gross profit (loss)
|
1,316,955 | 771,919 | 356,131 | (61,240 | ) | 2,383,765 | ||||||||||||||
Operating expenses:
|
||||||||||||||||||||
Sales and marketing
|
1,120,897 | 599,395 | 14,600 | 131,159 | 1,866,051 | |||||||||||||||
General and administrative
|
- | - | - | 4,155,792 | 4,155,792 | |||||||||||||||
Loss from investment in affiliate
|
- | - | - | 33,281 | 33,281 | |||||||||||||||
Operating expenses
|
1,120,897 | 599,395 | 14,600 | 4,320,232 | 6,055,124 | |||||||||||||||
Operating income (loss)
|
$ | 196,058 | $ | 172,524 | $ | 341,531 | $ | (4,381,472 | ) | $ | (3,671,359 | ) |
Core Standards and
|
Scientific and
|
|||||||||||||||||||
Contract Services
|
Ingredients
|
Regulatory
Consulting
|
||||||||||||||||||
At September 27, 2014 |
segment
|
segment
|
segment
|
Other
|
Total
|
|||||||||||||||
Total assets
|
$ | 3,394,033 | $ | 2,618,062 | $ | 277,007 | $ | 2,410,049 | $ | 8,699,151 |
Core Standards and
|
Scientific and
|
|||||||||||||||||||
Contract Services
|
Ingredients
|
Regulatory
Consulting
|
||||||||||||||||||
At December 28, 2013 |
segment
|
segment
|
segment
|
Other
|
Total
|
|||||||||||||||
Total assets
|
$ | 2,952,270 | $ | 1,083,856 | $ | 139,765 | $ | 4,811,001 | $ | 8,986,892 |
Exhibit No . | Description of Exhibits | |
10.1
|
First Amendment to the License Agreement, effective as of September 5, 2014 between the Regents of the University of California and ChromaDex, Inc.
(1)
|
|
31.1
|
Certification of the Chief Executive Officer pursuant to §240.13a−14 or §240.15d−14 of the Securities Exchange Act of 1934, as amended
|
|
31.2
|
Certification of the Chief Financial Officer pursuant to §240.13a−14 or §240.15d−14 of the Securities Exchange Act of 1934, as amended
|
|
32.1
|
Certification pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002)
|
(1)
|
A redacted version of this Exhibit is filed herewith. An un-redacted version of this Exhibit has been separately filed with the Commission pursuant to an application for confidential treatment. The confidential portions of the Exhibit have been omitted and are marked by an asterisk.
|
1.
|
Amend
the
BACKGROUND
of the License Agreement as follows:
|
|
1.1.
Replace
Paragraph A in its entirety with the following:
|
·
|
UC Case No. 2011-432 “Method for Inducing UDP-Glucuronosyltransferase Activity Using Pterostilnene” (“
Joint Invention
”),
|
·
|
UC Case No. 2014-036 “
Prevention of UV-induced hyperplasia and DNA damage in skin by Pterostilbene
” (also a “
Regents’ Invention
”); and
|
·
|
UC Case 2014-037 “
Prevention of UV-induced loss of barrier function in skin by Pterostilbene”
(also a “
Regents’ Invention
”)
|
2.
|
Replace
the definition of Net Sale in the License Agreement with the following definition to simplify the calculation of Net Sales of Combination Products:
|
|
“1.12 “Net Sale” means:
|
|
1.12.1
|
the Net Invoice Price, except in the instances described in Paragraphs 1.12.2 and 1.12.3 of this Agreement;
|
|
1.12.2 for any Relationship-Influenced Sale of a Licensed Product, Net Sales shall be based only on the Net Invoice Price at which the Relationship-Influenced Sale Purchaser re-Sells such Licensed Product to a Third Party (and the Relationship-Influenced Sale itself shall not be deemed a Sale); and
|
|
1.12.3 in those instances where Licensed Product is not Sold, but is otherwise commercially exploited by the Licensee, an Affiliate of the Licensee, or a Sublicensee, the Net Sales for such Licensed Product shall be the Net Invoice Price of such Licensed Product Sold to Third Parties in similar quantities by the Licensee, an Affiliate of the Licensee or a Sublicensee, as applicable.
|
3.
|
Update
the definition of Patent Rights in the License Agreement by replacing it in its entirety with the following:
|
4.
|
Update
Exhibit A (Patent Rights) of the License Agreement by replacing it in its entirety with the following:
|
UC Case Number
|
Application Number
|
Filing Date
|
2011-432
|
61/484977
|
5/11/2011
|
2011-432
|
13/466,827
|
5/8/2012
|
2011-432
|
PCT/US2012/064993
|
11/14/2012
|
2014-036
|
62/046,065
|
9/4/2014
|
2014-037
|
62/046,068
|
9/4/2014
|
5.
|
Add
a definition for the term “Non-Pharmaceutical Licensed Product” with new paragraph 1.26 as follows:
|
6.
|
Amend
Paragraph 2.8 of the License Agreement reflect The Regent’s policies and licensing practices by replacing it in its entirety with the following:
|
7.
|
Delete
Paragraph 2.9 of the License Agreement to reflect The Regent’s policies and licensing practices.
|
8.
|
Delete
Paragraph 4.7 of the License Agreement regarding Earned Royalties for Sales to the US Government to reflect The Regents’ current understanding of The Regents’ obligations.
|
9.
|
Amend
Article 6 of the License Agreement to reflect the value of additional Patent Rights added to the License Agreement by replacing this article in its entirety with the following:
|
i.
|
[*] Dollars ($[*]) on the 2
nd
anniversary date of the Effective Date
|
ii.
|
[*] Dollars ($[*]) on the 3
rd
anniversary of the Effective Date
|
iii.
|
[*] Dollars ($[*]) on the 4
th
anniversary of the Effective Date
|
iv.
|
[*] Dollars ($[*]) on the 5
th
anniversary of the Effective Date and each anniversary thereafter.
|
6.2
|
For each Non-Pharmaceutical Licensed Product reaching the milestones indicated below, Licensee must make the following milestone payments to The Regents within Thirty (30) days of reaching such milestone. Milestone payments are due from Licensee irrespective of whether the milestone listed below was reached by the Licensee itself, a third party acting on Licensee’s behalf, or by a Sublicensee or Affiliate.
|
i.
|
[*] Dollars ($[*]) due upon completion of safety studies
|
ii.
|
[*] Dollars ($[*]) due upon completion of efficacy studies
|
iii.
|
[*] Dollars ($[*]) due upon completion of stability studies
|
iv.
|
[*] Dollars ($[*]) due upon the first commercial sale
|
10.
|
Add
the following Paragraph 7.2 to the License Agreement to cover Sublicense Fees for the sales of Non-Pharmaceutical Licensed Products:
|
10.2.1
|
[*] percent ([*]%) of Attributed Income from Sublicense Agreements related to Non-Pharmaceutical Licensed Products; and
|
10.2.2
|
[*] of consideration due to the Licensee from the Sale of Non-Pharmaceutical Licensed Products by each Sublicensee, provided that such amount is not less than [*]% of Net Sales of Non-Pharmaceutical Licensed Products Sold by such Sublicensee.”
|
11.
|
Amend
Paragraph 8.2 of the License Agreement to include the sublicensee royalty payments resulting from the Net Sales of Non-Pharmaceutical Licensed Products Sold by a Sublicensee in the royalty stacking section by replacing this paragraph in its entirety with the following:
|
12.
|
Amend
Paragraph 8.3 of the License Agreement to reflect the value of additional Patent Rights added to the License Agreement by replacing this paragraph in its entirety with the following:
|
13.
|
Add
Paragraph 10.7 to the License Agreement to add additional diligence items reflecting the additional Patent Rights added to this Agreement as follows:
|
|
“
10.7
|
The Licensee, its Affiliates or Sublicensees will, or will cause a Third Party to develop a Non-Pharmaceutical Licensed Product according to the following development schedule:
|
|
The rights of The Regents detailed in Paragraph 10.4 and the rights of the Licensee in Paragraph 10.5 of this Agreement also apply to the diligence items in this Paragraph 10.7.”
|
14.
|
Amend
Article 19 (PATENT PROSECUTION AND MAINTENANCE) of the License Agreement to reflect how patent prosecution is being managed by the parties by deleting Paragraphs 19.1,19.2,19.5, and 19.7-19.9 in their entirety and replacing them with the following paragraphs 19.1 and 19.2:
|
15.
|
All other terms and conditions of the License Agreement remain the same.
|
CHROMADEX, INC. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | |
By: /s/ Troy Rhonemus | By: /s/ Ronnie Hanecak | |
Name: Troy Rhonemus | Name: Ronnie Hanecak, PhD | |
Title: COO | Title: Assistant Vice Chancellor | |
Date: September 19, 2014 | Date: September 5, 2014 |